Back to top

gene-editing: Archive

Zacks Equity Research

CRISPR (CRSP) Q4 Earnings Surpass Estimates, Sales Miss

CRISPR Therapeutics' (CRSP) fourth-quarter 2022 loss is narrower than expected, while sales miss estimates.

VRTXPositive Net Change ADMANegative Net Change CRSPNegative Net Change EFTRNo Net Change

Zacks Equity Research

Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging

Vertex Pharmaceuticals' (VRTX) four-quarter 2022 earnings and sales beat estimates. VRTX also issues better-than-expected revenue guidance for 2023.

VRTXPositive Net Change MRNANegative Net Change CRSPNegative Net Change RCUSPositive Net Change